NCT02453048已完成1 期
Phase Ib (High Dose), Single Centre, Dose-escalating, Placebo-controlled, Randomized Study of a Live Attenuated B. Pertussis Strain Given as a Single Intranasal Dose to Healthy Adult Volunteers
Institut National de la Santé Et de la Recherche Médicale, France2 个研究点 分布在 1 个国家目标入组 54 人开始时间: 2015年9月1日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 54
- 试验地点
- 2
- 主要终点
- The Primary Safety Endpoint is the Number and Percentage of Participants Per Dose Group and Randomized Allocation, With at Least One of the Following Adverse Events Between Day 0 and Day 28
研究概览
简要总结
This study evaluates the safety and immunogenicity of a higher dose formulation of a new live attenuated vaccine, BPZE1, intended to prevent Bordetella pertussis nasopharyngeal colonization and pertussis disease, and investigates whether higher doses of BPZE1 induce the live vaccine to colonize subjects' nasopharynx. The study is a Phase Ib (high dose), single centre, dose-escalating, placebo-controlled study of the live attenuated B. pertussis strain BPZE1 given as a single intranasal dose to healthy adult volunteer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 32 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy individual between 18 and 32 years of age, vaccinated or unvaccinated with acellular pertussis vaccine.
- •Female subject of child bearing potential must be willing to ensure that they use a highly efficient method of contraception during the study (e.g. contraceptive pill, intrauterine contraceptive device).
- •Informed consent form (ICF) signed by the subject.
- •Subject shall be able to attend all scheduled visits and to understand and comply with the study procedures.
排除标准
- •Individual with PT and/or PRN serum IgG antibodies ≥20 International units/ml (IU/ml). NOTE! One control group with PRN serum IgG antibodies ≥ 20 IU/ml will be included.
- •Vaccinated with the study vaccine in the Child Innovac study (EudraCT number 2010-019936-11).
- •Pregnant or lactating women. Pregnancy not planned and to be avoided during the study by use of effective contraceptive methods.
- •Blood pressure after resting ≥ 150/90 mm Hg at screening.
- •Heart rate after resting ≥ 80 bpm at screening.
- •Respiratory rate after resting ≥ 20/minute at screening.
- •Unwillingness to refrain from the use of nicotine products from screening through day
- •Use of narcotic drugs and/or a history of drug/alcohol abuse with in the past 2 years prior to screening
- •The subject has donated blood or suffered from blood loss of at least 450 ml (1 unit of blood) within 60 days prior to screening or donated plasma within 14 days prior to screening.
- •Receipt of immunoglobulin, blood derived products, systemic corticosteroids or other immunosuppressant drugs within 90 days prior to day
- •Asthma or other chronic respiratory problems.
- •Use of corticosteroids in the respiratory tract (e.g. nasal steroids, inhaled steroids) with in 30 days prior to day
- •Receipt of a vaccine within the last 30 days prior to day 0 or planned vaccination with in the next 30 days after day
- •Known hypersensitivity to any component of the study vaccine.
- •Current participation in any other clinical trial or participation (and during the whole study) in any clinical trial in the previous 3 months prior to day
- •Inability to adhere to the protocol, including plans to move from the area.
- •Family (first degree) history of congenital or hereditary immunodeficiency.
- •Past or present infection with HIV, hepatitis B or C.
- •Chronic conditions requiring ongoing active medical interventions, such as diabetes mellitus or cardiovascular disease.
- •Any autoimmune or immunodeficiency disease/condition (inherited or iatrogenic).
- •Any medical condition which, in the opinion of the investigator, might interfere with the evaluation of the study objectives or might affect the safety of the individual, e.g. evolving encephalopathy not attributable to another identifiable cause within 7 days of administration of a previous dose of any vaccine, hospitalization due to major depression or history of suicidal attempt.
- •Abnormal laboratory values outside the limit of normal values for the screening laboratory with clinical significance at the discretion of the investigator.
- •Person in frequent contact with children less than 1 year of age (parent, childcare worker, nurse, etc) or residence in the same household as persons with known immunodeficiency including persons on immunosuppressant therapy.
结局指标
主要结局
The Primary Safety Endpoint is the Number and Percentage of Participants Per Dose Group and Randomized Allocation, With at Least One of the Following Adverse Events Between Day 0 and Day 28
时间窗: 28 days
Percentage is based on subjects experiencing at least one of the following events: * Cough and spasmodic cough of grade 2 or higher * Other respiratory tract AE related or possibly related to vaccination of grade 3 or higher * Any other AE related or possibly related to vaccination of grade 3 or higher
次要结局
- The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination(6 months)
- Proportion of Subjects With BPZE1 Colonization(28 days)
研究者
研究点 (2)
Loading locations...
相似试验
Unknown
1 期
Dose Escalation Study of Interleukin-7 (IL-7) and Bitherapy in HCV Genotype 1 or 4 Patients Resistant to Bitherapy AloneHepatitis CNCT01025297Cytheris SA18
已完成
2 期
A Study of the Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Subjects Aged 65 Years and OlderInfluenzaNCT02553343Sanofi Pasteur, a Sanofi Company792
已完成
1 期
First Adult Safety Trial on Nasal Live Attenuated B. Pertussis VaccinePertussisNCT01188512Institut National de la Santé Et de la Recherche Médicale, France48
进行中（未招募）
2 期
Immunogenicity and Safety of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 30 Years and AboveHerpes ZosterNCT05856084MAXVAX Biotechnology Limited Liability Company924
终止
1 期
Phase 1/2a Trial of Pf GAP p52-/p36- Sporozoite Malaria VaccineMalariaNCT01024686Seattle Children's Hospital6